•Proactive Capital is an IR firm that is listed as a partner of The Dream Team Group.
•Documents show that Proactive has been paying writers to write bullish articles on Inovio and Unilife (among others).
•No disclosure of payments has been made.
•Dozens of additional articles have been and are being removed from identified paid authors on various stocks.
The U.S. National Institutes of Health last week gave a five-year grant of as much as $28 million to Saphire’s group, which is collaborating on antibody cocktails to fight Ebola. Saphire said she didn’t know if any of the experimental treatments were being used in the Guinea outbreak.
While HIV, the AIDS-causing virus that also jumped from animals to humans in Africa, has spawned dozens of approved drugs and a $14 billion market, the small number of Ebola cases is a deterrent for big drug companies, said Stephan Guenther, head of the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany.
“If you count all the cases of Ebola since the discovery, it’s below 10,000, so it’s definitely not of commercial interest,” he said by phone.
Guenther led a team of researchers that showed an experimental treatment called favipiravir, developed by Fujifilm Holdings Corp.’s Toyama Chemical unit as a treatment against the flu, cleared Ebola virus and prevented mice from dying in a study published in February.
Still, there is no clear path to commercialization given the challenge of testing the drug in humans, Yoshinobu Izumi, a spokesman for the unit, said by phone from Tokyo today.
Among the most promising drugs in development are antibody cocktails. One is being developed at Canada’s National Microbiology Laboratory, though it needs more work before it can be tested in humans, Public Health Canada said in an e-mail.
Mapp Biopharmaceutical Inc., a closely held company in San Diego, is developing another, along with the Defense Advanced Research Projects Agency, the NIH and the Defense Threat Reduction Agency.
That cocktail prevented 43 percent of monkeys with symptoms of Ebola from dying in a study published last year in Science Translational Medicine. Previous studies showed the treatment, called MB-003, saved all of the monkeys when given an hour after exposure to the virus, and two-thirds of the animals when administered 48 hours after exposure.
Two cancer drugs from Novartis AG, Gleevec and Tasigna, also fought the Ebola virus in laboratory experiments, according to a study published in 2012. GlaxoSmithKline Plc last year paid 250 million euros ($345 million) for Okairos AG, a Swiss vaccine developer with early-stage products against diseases including Ebola.
Inovio Pharmaceuticals Inc. of Blue Bell, Pennsylvania, said last year its experimental vaccine protected guinea pigs against the virus. Inovio is looking to partner with a government agency to move the program forward, Chief Operating Officer Niranjan Sardesai said by phone yesterday.
“Ebola is challenging because of a lack of good animal models,” he said.
The virus can cause sudden fever and intense weakness which is followed by vomiting, diarrhea and internal and external hemorrhaging. The disease has a fatality rate of as much as 90 percent, making it one of the most feared infectious diseases.
The virus, first identified in 1976 near the Ebola River in what is now the Democratic Republic of the Congo, is transmitted to people through the blood and other secretions of wild animals such as chimpanzees, gorillas, bats and porcupines, according to the WHO. Humans transmit the virus to each other through contact with blood and other body fluids.
V..Some day we all will laugh at this...............................................from our yachts!!
Think about it..I think some research was done and best in class prevails AGAIN !!
industry as judged by a panel of global biotech industry stakeholders.
Inovio was given accolades by its industry peers for "Best Therapeutic Vaccine," for its novel immunotherapy for cervical pre-cancers; "Best Licensing Deal," for its $400 million collaboration with Roche for Inovio's DNA-based immunotherapies for prostate cancer and hepatitis B; and, "Best Early Stage Vaccine Biotech," for its ability to raise funds and build its broad pipeline of immunotherapies and DNA vaccines.
The "Best Therapeutic Vaccine" award recognizes VGX-3100, Inovio's DNA vaccine designed to treat HPV-caused cervical dysplasia as well as cervical cancer, head and neck cancer, and anogenital cancers caused by HPV. Inovio is currently assessing the ability of VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial, with results expected mid-year 2014. In previous human studies this therapeutic vaccine demonstrated that it not only drives robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses display a powerful killing effect against cells changed by HPV into pre-cancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and various cancers caused by HPV. These data have been published in the peer-reviewed journal, Science-Translational Medicine.
"The Best Vaccine Licensing Deal" recognizes industry business combinations that possess the greatest potential for success in bringing innovative medicine to the market. Last year, Inovio signed a $400 million collaborative agreement with pharma giant Roche to co-develop Inovio's therapeutic vaccines for prostate cancer (INO-5150) and hepatitis B (INO-1800). The deal provided Inovio with an upfront payment of USD $10 million. Roche is paying for all preclinical and clinical development costs. Development and commercial milestones amount to potentially $412.5 million. Additional development milestones are payable if Roche pursues other indications with INO-5150 or INO-1800. Inovio is entitled to receive up to double-digit tiered royalties on product sales.
Inovio was also selected as "The Best Early Stage Vaccine Biotech" for its pioneering work to advance its portfolio of DNA vaccines to clinical stage candidates, with notable phase II study results of its lead immunotherapy forthcoming in the months ahead. Corporately, Inovio has raised over $120 million in the capital markets in the past year and established a major collaboration with Roche.
Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate the World Vaccine Congress' recognition of Inovio's leadership and innovation in advancing a vital new generation of immune-system-stimulating therapies and vaccines."
About the ViE Awards
The World Vaccine Congress & Expo, now in its 14th year, is the largest and most comprehensive event in the industry. Covering everything from the latest R&D to manufacturing to corporate development strategies, the Congress hosts the only awards ceremony dedicated to the vaccine industry. The ViE Awards honor individuals, organizations and initiatives which have made significant contributions over the past 12 months to innovation in the field of vaccines.
The technicals were filled,I cant believe we would go back that far but we did.Now we may retrace our gains. Somewhat.
It goes up tomorrow and they forget everything..but it makes a good story..
You have to click your heels Twice..
I know,.every 3 mo. or so I like to say.."so much potential, so little price".dead .dogs get up and walk and dead cats bounce ,we're just to early to the dance..type A,,
!0.00 to 300.00 dollars down the road or some ware in-between ...That behind me, I wonder if I'm sitting so pretty, so lucky to be here so early at such an opportune time,time is on our side,and time will tell.If we ,stay diligent and focused,I see a bright future for all of us..lol..." Stay thirsty my friends"